Ex vivo culture of circulating tumour cells derived from non-small cell lung cancer
Authors:
- Joanna KapelerisJKJoanna Kapeleris
- Arutha KulasingheAKArutha Kulasinghe
- Majid Ebrahimi WarkianiMWMajid Ebrahimi Warkiani
- Connor OlearyCOConnor Oleary
- Ian VelaIVIan Vela
- Paul LeoPLPaul Leo
- Peter SternesPSPeter Sternes
- Kenneth O’bYrneKOKenneth O’bYrne
- Chamindie PunyadeeraChamindie Punyadeera
Open Access
- 1 October 2020
- journal article
- research article
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 9 (5) , 1795-1809
Abstract
Background: Tumour tissue-based information is limited. Liquid biopsy can provide valuable real-time information through circulating tumour cells (CTCs). Profiling and expanding CTCs may provide avenues to study transient metastatic disease. Methods: Seventy non-small cell lung cancer (NSCLC) patients were recruited. CTCs were enriched using the spiral microfluidic chip and a RosetteSep™ using bloods from NSCLC patients. CTC cultures were carried out using the Clevers media under hypoxic conditions. CTCs were characterized using immunofluorescence and mutation-specific antibodies for samples with known mutation profiles. Exome sequencing was used to characterized CTC cultures. Results: CTCs (>2 cells) were detected in 38/70 (54.3%) of patients ranging from 0 to 385 CTCs per 7.5 mL blood. In 4/5 patients where primary tumours harboured an EGFR exon 19 deletion, this EGFR mutation was also captured in CTCs. ALK translocation was confirmed on CTCs from a patient harbouring an ALK-rearrangement in the primary tumour. Short term CTC cultures were successfully generated in 9/70 NSCLC patients. Whole exome sequencing (WES) confirmed the presence of somatic mutations in the CTC cultures with mutational signatures consistent with NSCLC. Conclusions: We were able to detect CTCs in >50% of NSCLC patients. NSCLC patients with >2 CTCs had a poor prognosis. The short-term CTC culture success rate was 12.9%. Further optimization of this culture methodology may provide a means by which to expand CTCs derived from NSCLC patient’s bloods. CTC cultures allow for expansion of cells to a critical mass, allowing for functional characterization of CTCs with the goal of drug sensitivity testing and the creation of CTC cell lines.Keywords
This publication has 71 references indexed in Scilit:
- Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and ErlotinibClinical Cancer Research, 2012
- Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2011
- Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancerJournal of Translational Medicine, 2010
- Isolation of circulating tumor cells using a microvortex-generating herringbone-chipProceedings of the National Academy of Sciences, 2010
- The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing dataGenome Research, 2010
- Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung CancerClinical Cancer Research, 2009
- Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial dataThe Lancet Oncology, 2009
- Detection of Mutations inEGFRin Circulating Lung-Cancer CellsNew England Journal of Medicine, 2008
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- Disease recurrence after resection for stage I lung cancerEuropean Journal of Cardio-Thoracic Surgery, 1997